Trial ID or NCT#





The purpose of the study is to determine whether investigators successfully collect blood and tissue samples in cancer patients receiving immunotherapy with a drug that blocks either PD-1 or PD-L1 (checkpoint inhibitor). Investigators will look for changes in the cancer cells pre and post immunotherapy. In an imaging sub-study, some participants will have a PET/CT scan with an investigational tracer, [18F]F-AraG, to examine if the tracer is a safe and effective way to visualize sites of immune system activation in cancer patients. Results of the main study could inform new treatment regimens, better predict who will respond to therapy, or identify new targets for drug development. Results of the imaging sub-study may help develop new non-invasive ways to monitor drug efficacy.

Official Title

A Pilot Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Quynh-Thu Le, MD, FACR, FASTRO
Radiation oncologist
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology-Head and Neck Surgery at the Stanford University Medical Center
Shyam Srinivas
Clinical Instructor, Radiology - Rad/Nuclear Medicine
Guido Davidzon
Clinical Assistant Professor, Radiology - Rad/Nuclear Medicine

Contact us to find out if this trial is right for you.


Nikita Bedi
(650) 723-5957